Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy
<b>Background/Objectives</b>: Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the <i>GBA1</i> gene. Type 1 Gaucher disease is characterised by substrate accumulation in the visceral organs, which occurs in combination with acut...
Saved in:
| Main Authors: | Amy F. Geard, Giulia Massaro, Michael P. Hughes, Patrick Arbuthnot, Simon N. Waddington, Ahad A. Rahim |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/5/650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of CRISPR/Cas9 technology in the modeling of Gaucher disorder
by: Mehran Reyhani-Ardabili, et al.
Published: (2024-12-01) -
Gaucher disease type 3 from infancy through adulthood: a conceptual model of signs, symptoms, and impacts associated with ataxia and cognitive impairment
by: Raphael Schiffmann, et al.
Published: (2025-04-01) -
Eliglustat substrate reduction therapy in children with Gaucher disease type 1
by: Noor Ul Ain, et al.
Published: (2025-02-01) -
Gaucher's disease - a review of the most important information about the disease in Paediatrics
by: Jakub Jarmołowicz, et al.
Published: (2025-07-01) -
Gaucher disease type 2 (case report)
by: D. R. Shagieva, et al.
Published: (2020-09-01)